Abstract
Background: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) worldwide and is estimated that ~20% of type 2 diabetics develop ESRD during their lifetime. In type 2 diabetics with microalbuminuria, both enalapril and telmisartan have shown to reduce microalbuminuria, thereby delaying the progression of renal disease in diabetics. Aim and Objective: This study aims to evaluate the efficacy of enalapril versus telmisartan among patients with DN for 6 months. Materials and Methods: A prospective, open-labeled, randomized, comparative study was conducted involving 100 type 2 diabetics with mild hypertension and Grade I DN was divided randomly into two groups of 50 each, aged between 18 and 69 years with either sex, attending medicine outpatient department or admitted in medicine wards. One group received tab. enalapril maleate, 510 mg/day, while other group received tab. telmisartan, 4080 mg/day, and were followed up once a month for 6 months. Efficacy was assessed using urine albumin, serum urea, serum creatinine, and blood pressure (BP). Results: Demographic and baseline urine albumin level, serum urea, serum creatinine, and BP were comparable between two groups. Early improvement in urine albumin and serum creatinine levels was seen with enalapril (at 2 months, urine albumin: P = 0; at 3 months, serum creatinine: P = 0.007). Reduction of BP was greater with telmisartan (systolic BP/diastolic BP (DBP): P < 0.001). In later phase, no significant difference was observed between two groups among the parameters such as urine albumin estimation (P = 1) and serum urea (P = 0.286). Conclusion: Both enalapril and telmisartan were equally efficacious in DN. However, enalapril had better response than telmisartan in our study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: National Journal of Physiology, Pharmacy and Pharmacology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.